Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Idiopathic Pulmonary Arterial Hypertension.

In brief

The purpose of this study is to determine if dynamic hyperinflation seen in patients with idiopathic pulmonary artery hypertension (iPAH) improves with albuterol therapy.

Key facts

Study ID

NCT02108743

Run by

American Medical Association Foundation

People needed

0

Starts

2014-06-01

Expected to finish

2016-10-01

Last updated by the study team

2015-12-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or greater.
• Idiopathic Pulmonary Arterial Hypertension, or Familial Pulmonary Arterial Hypertension.
• Forced expiratory flow 75% (FEF75%) of ≤ 65% of predicted.

You may not qualify if…

• Clinical instability or change in medication therapy in preceding 3 months.
• Allergy or intolerance to inhaled albuterol.
• Body mass index > 30
• Active tobacco use, or > 10 pack-year smoking history.
• Lung disease other than pulmonary hypertension
• Forced expiratory volume in 1 second (FEV1) ≤ 80% of predicted.
• Pregnancy
• Inability to perform pulmonary function testing.
• Inability to perform cardiopulmonary exercise testing.
• Supplemental oxygen requirement.
• Inability to read and understand English.
• Historical 6-minute walk distance <150 meters

Where it is running

• LSUHSC Interim Louisiana Hospital — New Orleans, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.